BidaskClub downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a sell rating in a research note released on Thursday morning, BidAskClub reports.

OSUR has been the topic of several other reports. Zacks Investment Research raised DLH from a sell rating to a hold rating in a research report on Tuesday, July 9th. Canaccord Genuity reaffirmed a hold rating and issued a $20.00 target price (down from $29.00) on shares of Sailpoint Technologies in a research report on Thursday, May 9th. Three equities research analysts have rated the stock with a sell rating and one has issued a hold rating to the company’s stock. The stock presently has an average rating of Sell and a consensus price target of $10.00.

Shares of OSUR stock traded up $0.07 on Thursday, hitting $8.53. 18,636 shares of the stock traded hands, compared to its average volume of 674,497. The company has a quick ratio of 6.56, a current ratio of 7.52 and a debt-to-equity ratio of 0.02. The company has a market cap of $525.56 million, a P/E ratio of 17.08, a PEG ratio of 2.93 and a beta of 1.21. OraSure Technologies has a 1-year low of $8.01 and a 1-year high of $17.32. The stock’s fifty day moving average is $8.74.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. OraSure Technologies had a return on equity of 7.87% and a net margin of 11.34%. The firm had revenue of $30.12 million for the quarter, compared to analyst estimates of $29.66 million. During the same period last year, the company earned $0.07 earnings per share. The firm’s revenue for the quarter was down 28.3% on a year-over-year basis. On average, analysts predict that OraSure Technologies will post 0.23 earnings per share for the current fiscal year.

In other OraSure Technologies news, SVP Jack E. Jerrett acquired 10,000 shares of OraSure Technologies stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $8.55 per share, with a total value of $85,500.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders have bought 21,000 shares of company stock valued at $184,360. 1.70% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of OSUR. Roble Belko & Company Inc acquired a new stake in OraSure Technologies in the 1st quarter valued at approximately $29,000. Parallel Advisors LLC bought a new position in OraSure Technologies in the 1st quarter valued at $33,000. Quantamental Technologies LLC bought a new position in OraSure Technologies in the 1st quarter valued at $56,000. Stone Ridge Asset Management LLC acquired a new stake in shares of OraSure Technologies in the 4th quarter valued at $131,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of OraSure Technologies in the 2nd quarter valued at $133,000. 91.51% of the stock is owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Article: What defines an oversold asset?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.